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OBJECTIVE — To study the effect of exenatide on body composition and circulating cardio-
vascular risk biomarkers.
RESEARCH DESIGN AND METHODS — Metformin-treated patients with type 2 di-
abetes (N  69) were randomized to exenatide or insulin glargine and treated for 1 year. Body
composition was evaluated by dual-energy X-ray absorptiometry. Additionally, body weight,
waist circumference, and cardiovascular biomarkers were measured.
RESULTS — Treatment with exenatide for 1 year signiﬁcantly reduced body weight, waist
circumference, and total body and trunkal fat mass by 6, 5, 11, and 13%, respectively. In
addition, exenatide increased total adiponectin by 12% and reduced high-sensitivity C-reactive
protein by 61%. Insulin glargine signiﬁcantly reduced endothelin-1 by 7%. These changes were
statistically independent of the change in total body fat mass and body weight.
CONCLUSIONS — Exenatidetreatmentfor1yearreducedbodyfatmassandimprovedthe
proﬁle of circulating biomarkers of cardiovascular risk. No signiﬁcant changes were seen with
insulin glargine except a trend for reduced endothelin-1 levels.
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A
bdominal obesity is associated with
both type 2 diabetes and metabolic
complications (1), including eleva-
tions in several circulating biomarkers of
cardiovascular risk (2). Most pharmaco-
logical glucose-lowering treatments in-
crease body weight (3). Therefore,
treatments that not only reduce A1C, but
also improve other associated changes
such as abdominal obesity are urgently
needed (4).
We previously reported in Diabetes
Care that exenatide improves glycemic
control to the same extent as insulin
glargine, although exenatide decreased
and insulin glargine raised body weight
(5). Herein we present additional data on
associated changes in body composition
and circulating levels of biomarkers of
cardiovascular risk after 1 year of
treatment.
RESEARCH DESIGN AND
METHODS— Details on study design
were reported previously (5). Patients
wererandomizedtoexenatide(n36)or
insulin glargine (n  33) added to their
ongoing metformin therapy (baseline
characteristics and patient disposition are
shown in supplemental Fig. 1 in the on-
line appendix available at http://care.
diabetesjournals.org/cgi/content/full/
dc09-2361/DC1).Thestudyprotocolwas
approved by each site’s ethics review
committee and was in accordance with
the principles described in the Declara-
tion of Helsinki. All participating patients
gave their written informed consent prior
to screening.
Dual-energy X-ray absorptiometry
scan
Lean body and fat mass was assessed us-
ing dual-energy X-ray absorptiometry
(DEXA) scans (Delphi A; Hologic,
Waltham, MA) at baseline and after treat-
ment. Trunk (abdominal) and limb (hip/
leg) regions of interest were determined
from a total body scan. Waist circumfer-
ence was measured at the midline of the
interval between the iliac crest and the
lowestribusingthemeanoftwomeasure-
ments prior to the DEXA scan.
Biochemical analyses
Cardiovascular risk biomarkers were
collected at baseline and after 1 year of
treatment. Serum was separated by
centrifugation and stored at 80°C until
analysis.Allserumsampleswereanalyzed
in the Lundberg Laboratory for Diabetes
Research using a single batch. Total adi-
ponectin, high molecular weight (HMW)
adiponectin, resistin, leptin, high-
sensitive C-reactive protein (hs-CRP), in-
terleukin (IL)-6, monocyte chemotactic
protein (MCP)-1, and endothelin-1 were
determined by commercial ELISAs (R&D
Systems, Abingdon, U.K.).
Statistical analysis
Non-normally distributed data were log-
transformed prior to statistical analysis,
after which they approximated the nor-
mal distribution. All outcome measures
are compared between the two treatment
groups using an ANCOVA model includ-
ing factors for treatment, investigative
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Department of Internal Medicine, Section of Endocrinology, Diabetes Center, VU University
Medical Center, Amsterdam, the Netherlands; the
2Lundberg Laboratory for Diabetes Research, Sahlg-
renskaUniversityHospital,Goteborg,Sweden;the
3DepartmentofMedicine,HelsinkiUniversityCentral
Hospital, Helsinki, Finland; the
4Minerva Medical Research Institute, Helsinki, Finland; the
5Eli Lilly and
Company, Houten, the Netherlands;
6Eli Lilly and Company, Indianapolis, Indiana.
Corresponding author: Mathijs C. Bunck, mcmbunck@vumc.nl.
Received 25 December 2009 and accepted 20 April 2010. Published ahead of print at http://care.
diabetesjournals.org on 27 April 2010. DOI: 10.2337/dc09-2361. Clinical trial reg. no. NCT00097500,
clinicaltrials.gov.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clinical Care/Education/Nutrition/Psychosocial Research
BRIEF REPORT
1734 DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 care.diabetesjournals.orgsite,andbaselineA1Cstratum(8.5%or
8.5%), and baseline values of corre-
sponding outcome measure as a covariate
(5). Statistical analysis was performed us-
ing SPSS 16.0 for Mac OS X (SPSS, Chi-
cago, IL). All inferential statistical tests
were conducted at a signiﬁcance level of
0.05 (two-sided).
RESULTS— Treatmentfor1yearwith
exenatide resulted in a statistically signif-
icantreductionintotalbodyfatmass(Ta-
ble 1), mainly in the abdominal region, as
illustrated by the decrease in trunk fat
massandwaistcircumference,incontrast
to insulin glargine. Neither treatment sig-
niﬁcantly affected lean body mass.
In univariate analysis, the reduction
in body weight in the exenatide arm was
signiﬁcantly correlated with the changes
in leptin (r  0.580, P  0.001) and hs-
CRP (r  0.590, P  0.001). No statis-
tically signiﬁcant univariate correlation
was found between changes in body
weight and other biomarkers. Interest-
ingly, changes in all circulating biomark-
ers did not correlate with the changes in
total body fat mass (total adiponectin:
Pearson 
2 test, r  0.224, P  0.106;
HMWadiponectin:r0.057,P0.694;
leptin:r0.229,P0.106;hs-CRP:r
0.023, P  0.872).
After multivariate analysis and statis-
tical adjustment for body weight change,
exenatide increased total adiponectin and
decreased hs-CRP concentrations,
whereas insulin glargine did not (Table
1). Insulin glargine reduced endothelin-1
concentrations, whereas exenatide did
Table 1—Body composition, circulating cardiovascular risk biomarkers and percentage change from baseline
n Baseline Endpoint
Percentage change from baseline
LS mean
Between-treatment
group difference P
Total fat mass (kg)
Insulin glargine 28 29.9  1.6 28.5  1.9 1% (7% to 5%)
Exenatide 29 27.8  1.4 25.4  1.6 11% (18% to 5%) 10% (16% to 4%) 0.003
Total lean mass (kg)
Insulin glargine 28 60.1  1.7 60.6  1.8 0% (1% to 2%)
Exenatide 29 57.8  2.1 58.1  2.4 0% (2% to 1%) 1% (3% to 1%) 0.480
Trunk fat mass (kg)
Insulin glargine 28 17.8  0.9 16.6  1.1 1% (8% to 5%)
Exenatide 29 16.3  0.8 14.8  1.0 13% (18 to 7%) 11% (18% to 4%) 0.002
Body weight (kg)
Insulin glargine 29 94.1  2.5 93.8  2.7 1% (3% to 1%)
Exenatide 30 90.3  2.4 86.4  2.6 6% (8% to 3%) 5% (7% to 2%) 0.001
Waist circumference (cm)
Insulin glargine 29 106.9  1.9 107.4  2.0 1% (1% to 3%)
Exenatide 30 106.1  1.9 100.6  2.1 5% (7% to 3%) 6% (8% to 4%) 0.001
Leptin (g/l)
Insulin glargine 29 7.79  1.29 8.41  1.53 7% (11% to 29%)
Exenatide 30 8.50  1.32 7.45  1.17 14% (27% to 2%) 19% (34% to 1%) 0.045
Total adiponectin (ng/ml)
Insulin glargine 29 4,648  461 4,508  436 5% (13% to 5%)
Exenatide 30 4,848  432 5,314  466 12% (3% to 21%) 17% (6% to 30%) 0.004
HMW adiponectin (ng/ml)
Insulin glargine 29 1,277  221 1,321  236 0% (24% to 31%)
Exenatide 30 1,571  255 1,850  273 19% (6% to 51%) 19% (12% to 61%) 0.253
hs-CRP (mg/l)
Insulin glargine 29 1.42  0.27 1.38  0.35 20% (50% to 27%)
Exenatide 30 1.81  0.25 1.30  0.22 61% (74% to 42%) 52% (71% to 19%) 0.008
IL-6 (pg/ml)
Insulin glargine 29 1.96  0.21 2.17  0.20 4% (26% to 25%)
Exenatide 30 2.11  0.22 2.10  0.25 10% (28% to 14%) 6% (30% to 26%) 0.670
MCP-1 (pg/ml)
Insulin glargine 29 1.22  0.07 1.24  0.07 1% (12% to 11%)
Exenatide 30 1.18  0.09 1.21  0.11 4% (13% to 7%) 2% (14% to 12%) 0.728
Resistin (ng/ml)
Insulin glargine 29 330  15 329  20 3% (13% to 7%)
Exenatide 30 316  14 311  16 0% (9% to 9%) 3% (8% to 16%) 0.577
Endothelin-1 (ng/ml)
Insulin glargine 29 2.57  0.18 2.46  0.19 7% (11% to 2%)
Exenatide 30 2.53  0.19 2.53  0.19 1% (5% to 3%) 6% (1% to 12%) 0.045
DataaremeansSEM(bodycompositionmeasures)orgeometricmeansSEM(cardiovascularbiomarkers)andbodyweightchange–adjustedleast-squaresmean
percentage change (95% CI) from baseline. LS, least-squares.
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ther treatment on HMW adiponectin,
IL-6, MCP-1, and resistin was observed.
The crude between–treatment group
differences remained statistically signiﬁ-
cant after additional multivariate adjust-
ment for total body fat mass change: total
adiponectin 16% (95% CI: 5% to
28%), P  0.004; leptin 20% (34%
to 2%), P  0.028; hs-CRP 48%
(69% to 13%), P  0.015; and body
weight change (Table 1): total adiponec-
tin 17% (95% CI 6% to 30%), P 
0.004; leptin 19% (34% to 0%), P 
0.045; hs-CRP 52% (71% to 19%),
P  0.008.
CONCLUSIONS — This study
showed that exenatide reduced body fat
massandimprovedtheproﬁleofcirculat-
ing cardiovascular biomarkers. The
changesinthedifferentbiomarkerscould
not be fully attributed to the observed
changes in body fat mass and body
weight. Direct effects of glucagon-like
peptide 1 (GLP-1) receptor agonists on
adipocyte function have been described
in both animal experimental studies and
in vitro studies in normal human adipo-
cytes (rev. in 6); however, as a signiﬁcant
univariate correlation between change in
body weight (not with fat mass) and car-
diovascular biomarkers was present, our
relatively small population may inﬂuence
the statistical power of our study.
Animal studies have also demon-
strated beneﬁcial effects of exenatide on
visceral fat mass (7) and circulating adi-
ponectin (8), leptin (9), and CRP (10)
concentrations. However, to the best of
our knowledge, controlled clinical stud-
ies on the long-term effects of GLP-1 re-
ceptor agonists on body composition and
biomarkers of cardiovascular risk have
not previously been reported.
A recent 3-month study comparing
exenatide to insulin glargine in 56 pa-
tients with type 2 diabetes has a design
comparable to our 1-year study. Similar
to our ﬁndings, this study showed that
exenatide treatment was associated with
reduced hs-CRP, without affecting the
IL-6 levels (11).
Subanalysis of the Liraglutide Effect
and Action in Diabetes (LEAD)-3 study
data reported that liraglutide treatment
for 52 weeks compared with treatment
with glimiperide reduced DEXA-
measured total fat tissue mass (12). Lean
tissue mass was also reduced after 1 year
of treatment, but as glimiperide also re-
ducedleantissuemass,thisreductionwas
not statistically signiﬁcantly different be-
tween the groups. Twenty-six-week data
from the LEAD-2 study was used to show
that the observed reduction in fat mass
was mainly a result of a reduction in vis-
ceral fat (12). Unfortunately, this study
did not report the effects of body compo-
sition on circulating biomarkers. Serum
leptin, hs-CRP, and IL-6 concentrations
did not change in a 14-week placebo-
controlled study with liraglutide 1.9 mg
(13).
Ofparticularinterestinourstudywas
the ﬁnding that the changes in biomark-
ers of cardiovascular risk appeared to be
independent of the changes in body fat
mass. Recently, Chung et al. reported ex-
endin-4 directly increased adiponectin
mRNAlevelsandsecretionin3T3-L1adi-
pocytes (14). In that study, exendin-4
also decreased mRNA levels of IL-6 and
MCP-1 (14). Additionally, we (15) and
others(10)havepreviouslyreportedben-
eﬁcial effects of exenatide on hepatic ste-
atosis, which also may contribute to a
reduction in CRP.
In conclusion, we found that ex-
enatide treatment for 1 year led to a re-
duced total fat mass, including visceral
fat, while lean body mass was not signiﬁ-
cantly altered. Additionally, the circulat-
ing levels of adiponectin, leptin, and hs-
CRP showed an improved proﬁle that
appeared to be independent of the
changesinfatmass.Incontrast,nosignif-
icant changes in body composition or cir-
culating biomarkers were seen with
insulin glargine.
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